SCHF - Schwab International Equity ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
-0.40 (-1.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close33.23
Bid0.00 x 0
Ask0.00 x 0
Day's Range32.83 - 33.35
52 Week Range29.45 - 36.35
Avg. Volume2,675,713
Net Assets14.63B
PE Ratio (TTM)N/A
YTD Return-0.73%
Beta (3y)0.96
Expense Ratio (net)0.06%
Inception Date2009-11-03
Trade prices are not sourced from all markets
  • 3 ETFs to Help You Build Retirement Wealth
    Motley Fool4 months ago

    3 ETFs to Help You Build Retirement Wealth

    These picks might surprise you, but they'll serve you well.

  • ETF.com7 months ago

    A Deeper Dive Into ESG ETF Portfolios

    The world is full of model ETF portfolios, but we’re just starting to see the environmental, socially responsible and governance (ESG) filter as a consideration on many. The biggest recent news on this front was the development by robo-platform Betterment of an ESG version of its core portfolio last month.

  • Market Realist8 months ago

    Novartis in 2Q17: Performance of Alcon

    For 2Q17, Alcon reported a 1.0% growth in revenues to $1.52 billion compared to $1.51 billion in 2Q16.

  • Benzinga8 months ago

    Rapid Growth For This International ETF

    Several of this year's top asset-gathering exchange traded funds are products focusing on developed market equities outside the U.S. Amid the rush to developed market ex-U.S. ETFs, another theme is becoming ...

  • Market Realist8 months ago

    Novartis’s 2Q17 Estimates: How Sandoz Might Perform

    Revenues for Sandoz are expected to report operational growth in 2Q17 following an increased demand for biopharmaceuticals.

  • Market Realist9 months ago

    Novartis Stock in 2Q17: How Has It Performed?

    Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products, mainly pharmaceuticals. ...

  • 3 Top International ETFs for 2017 and Beyond
    Motley Fool9 months ago

    3 Top International ETFs for 2017 and Beyond

    Exchange-traded funds that hold only foreign stocks can add diversification and high growth potential to your portfolio.

  • Forbes9 months ago

    The Single-Best Retirement Fund Booster

    You can make one solid move this year to boost your retirement savings. Here's what you need to know.

  • Market Realist10 months ago

    Inside Novartis’s Innovative Medicines Segment in 1Q17

    Novartis’s (NVS) Innovative Medicines segment contributed ~67% of NVS's total revenues in 1Q17.

  • Market Realist10 months ago

    GlaxoSmithKline’s Pharmaceuticals Segment in 1Q17

    The Pharmaceuticals segment reported an operational growth of 4.0% and a 13.0% positive impact of foreign exchange, resulting in a rise of 17.0% in revenues.

  • Market Realist10 months ago

    How AstraZeneca’s Growth Platforms Performed in 1Q17

    A few of the segments AstraZeneca identifies as growth platforms include Respiratory products, new Cardiovascular and Metabolic Diseases products, and new Oncology products.

  • Market Realist10 months ago

    Performance of Sanofi Genzyme in 1Q17

    Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.

  • Market Realist11 months ago

    Novartis’s 1Q17 Earnings: Recent Developments

    On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.

  • Investopedia11 months ago

    A Deal on Developed Markets Exposure

    Investors seeking low fees on developed markets exposure should look at this ETF.

  • ETF.comlast year

    World’s Cheapest ETF Portfolio Just Got Cheaper

    [Editor’s Note: Due to a data error, an earlier version of this article suggested that the newly launched IDEV had taken over as the cheapest international developed-market equity ETF. In fact, the Schwab International Equity ETF (SCHF) remains the cheapest fund in that category, with an expense ratio of 0.06%. We apologize for the error, which has been corrected below.]

  • Market Realistlast year

    Novartis’s Recent Developments

    On January 6, 2017, Novartis announced a collaborative agreement with Ionis Pharmaceutical (IONS) and its subsidiary, Akcea Therapeutics.